Full-Time

Senior Digital Medical Science Liaison

Posted on 12/13/2025

Travere Therapeutics

Travere Therapeutics

501-1,000 employees

Develops and commercializes rare-disease therapies

Compensation Overview

$170k - $221k/yr

+ Base Pay + Short-Term Incentive + Long-Term Incentive (Company stock)

Remote in USA

Remote

Remote work from the USA; expect up to ~50% travel for congresses and external engagements.

Category
Biology & Biotech (2)
,
Required Skills
Data Analysis
Requirements
  • Advanced degrees are strongly preferred (PharmD, PhD, MD/DO, PA, or NP) in a relevant scientific discipline; equivalent scientific education and experience will be considered.
  • Minimum 5 years’ experience in a Medical Affairs or MSL role within the biopharmaceutical industry ideally with exposure to digital or omnichannel initiatives; consideration will be made with comparable experience in research and/or pharmaceutical experience.
  • Experience engaging HCPs via digital platforms and CRM platforms (e.g., Veeva), social listening tools, and digital analytics platforms.
  • Strong digital fluency, analytical mindset, and ability to derive actionable insights from data.
  • Excellent communication and relationship-building skills in both virtual and live settings.
  • Knowledge of nephrology, rare disease, or similar specialty areas a plus.
  • Willingness to travel up to ~50% for congresses, team meetings, or external engagements.
Responsibilities
  • Identify and engage with scientifically credible Digital Opinion Leaders (DOLs) in relevant therapeutic areas, including digitally active healthcare professionals (HCPs), academic researchers, clinical experts and other influencers.
  • Cultivate professional, compliant relationships with DOLs to enable peer-to-peer scientific exchange and foster mutual understanding of evolving medical landscapes via virtual and live channels.
  • Demonstrate deep scientific expertise about assigned molecules/products and overall therapeutic areas to exchange relevant information and insights with digital influencers across the US.
  • Serve as a key driver and educator on the benefits and limitations and scientific evidence supporting digital health innovations (e.g., wearables, EHR tools, etc.) for internal and external stakeholders.
  • Build and cultivate important working relationships with therapeutic MSLs to ensure an enterprise approach when working across internal and external stakeholders.
  • Monitor and analyze conversations across digital platforms (e.g., X/Twitter, LinkedIn, Reddit, YouTube) to capture emerging scientific trends, key topics, HCP sentiment, and patient experiences.
  • Capture and synthesize real-time insights related to products, therapeutic areas of interest, unmet needs, and HCP experiences.
  • Escalate potential issues or misinformation that may pose reputational risk, ensuring timely communication and resolution planning.
  • Develop reports in collaboration with the Digital Engagement and Innovation team summarizing social media trends, digital trends, reputational insights, competitive intelligence, and scientific discourse to inform omnichannel strategy.
  • Contribute to the development of KPIs and benchmarks to measure digital engagement quality, reach, and social impact over time.
  • Contribute to internal training and awareness of the evolving digital medical landscape and the role of DOLs in shaping scientific discourse.
  • Serve as a digital engagement expert and liaison between field medical and internal teams (e.g., Digital Engagement and Innovation, Scientific Communications).
  • Partner with therapeutic MSLs to align on emerging trends, stakeholder needs, and integrated field strategies.
  • Collaborate cross-functionally to support medical content development tailored for digital consumption and aligned with the needs and communication styles of digital medical influencers.
  • Serve as a bridge between internal teams and the external digital medical community, translating real-world DOL perspectives into actionable insights to inform medical strategy, clinical development, and publications planning.
  • Engage in continuous learning within the therapeutic area represented and actively attend and participate in upskilling programs related to assigned molecules, products, disease states and digital health technologies including telemedicine, mobile apps, wearable devices, artificial intelligence, data analytics and electronic health records.
  • Build and cultivate important working relationships across internal field partners to ensure an enterprise approach when working with internal and external stakeholders.

Travere Therapeutics develops and commercializes therapies for rare diseases, especially kidney and metabolic disorders. It has commercial products Thiola and Thiola EC for cystinuria and Chenodal for gallstones, with a pipeline that includes sparsentan for focal segmental glomerulosclerosis and IgA nephropathy. The company generates revenue from the sale of its products and supports patients through a dedicated patient assistance program. Its approach centers on identifying and delivering treatments for rare diseases, combining commercialization with ongoing drug development.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • FILSPARI Q1 2026 sales hit $105.2 million, up 88% year-over-year.
  • FSGS approval expands US addressable market beyond 100,000 patients.
  • Chugai submits sparsentan NDA in Japan 2026, triggering milestone payments.

What critics are saying

  • Robbins Geller investigates Travere for securities violations since January 2026.
  • Ligand claims 9% royalty on all worldwide FILSPARI sales.
  • Novartis atrasentan Phase III threatens 20-30% FILSPARI market share.

What makes Travere Therapeutics unique

  • FILSPARI is first FDA-approved therapy for FSGS in patients aged 8 and older.
  • FILSPARI leads IgAN market as most prescribed FDA-approved medicine.
  • Pegtibatinase advances as novel Phase 3 enzyme replacement for classical homocystinuria.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Wellness Program

Company Equity

Company News

Yahoo Finance
Apr 14th, 2026
Travere's FILSPARI receives FDA approval for FSGS, earns Ligand 9% royalty on sales

Ligand Pharmaceuticals' partner Travere Therapeutics has received FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS) in adult and paediatric patients aged eight and older without nephrotic syndrome. FILSPARI becomes the first and only FDA-approved medicine for FSGS, a rare kidney disorder and leading cause of kidney failure. The approval expands FILSPARI beyond IgA nephropathy, where it is already the most commonly prescribed FDA-approved medicine. Ligand is entitled to a 9% royalty on worldwide net sales. Travere estimates the addressable US population exceeds 30,000 individuals with FSGS without nephrotic syndrome. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 48% reduction in proteinuria compared to 27% for irbesartan in patients without nephrotic syndrome.

Yahoo Finance
Apr 13th, 2026
FDA fully approves FILSPARI for FSGS, first treatment for rare kidney disease affecting 30K US patients

Travere Therapeutics announced that the FDA has granted full approval for FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) who do not have nephrotic syndrome. FILSPARI is the first and only FDA-approved medicine for FSGS. The approval expands FILSPARI's addressable population to more than 100,000 patients in the US, including over 30,000 with FSGS. The drug is already the most commonly prescribed FDA-approved medicine for IgA nephropathy. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 46% reduction in proteinuria compared to 30% for irbesartan. In patients without nephrotic syndrome specifically, the reduction was 48% versus 27%. The medicine was generally well tolerated across adult and paediatric patients.

The Motley Fool
Jan 25th, 2026
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? | The Motley Fool

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

The Motley Fool
Jan 24th, 2026
Palisades Investment buys $5.3M stake in Travere Therapeutics as shares surge 51%

Palisades Investment Partners initiated a new position in Travere Therapeutics worth $5.26 million, acquiring 137,768 shares in the fourth quarter of 2025, according to an SEC filing. The stake represents 1.99% of the fund's $264.72 million in reportable US equity assets. Travere Therapeutics, a biotechnology company specialising in rare disease therapies, has seen its shares rise 50.89% over the past year to $27.87. The company's revenue surged to $164.9 million in the third quarter, driven by a 155% year-over-year increase in sales of its FILSPARI drug to $90.9 million. The timing of Palisades' investment coincided with FDA review of FILSPARI for potential expanded approval in focal segmental glomerulosclerosis treatments, suggesting confidence in the company's growth prospects.

GlobeNewswire
Jan 13th, 2026
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

TVTX ALERT: investigation launched into Travere Therapeutics, Inc., RGRD law attorneys encourage investors and potential witnesses to contact law Firm. SAN DIEGO, Jan. 13, 2026 (GLOBE NEWSWIRE) - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. THE COMPANY: Travere is a biopharmaceutical company that develops therapies for people living with rare kidney and metabolic diseases in the United States. THE INVESTIGATION: Robbins Geller is investigating whether Travere and certain of its top executives made materially false and/or misleading statements and/or omitted material information regarding Travere's business and operations. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases - more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever - $7.2 billion - in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.

INACTIVE